Psychosomatic Medicine Faster Service from Outside North America
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russo, S.
Right arrow Articles by Korf, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russo, S.
Right arrow Articles by Korf, J.
Related Collections
Right arrow Immunology
Right arrow Depression
Right arrow Therapeutic Interventions
Psychosomatic Medicine 67:773-777 (2005)
© 2005 American Psychosomatic Society

ORIGINAL ARTICLES

Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism

Sascha Russo, MD, PhD, Ido P. Kema, PhD, Elizabeth B. Haagsma, MD, PhD, Jim C. Boon, MD, Pax H.B. Willemse, MD, PhD, Johan A. den Boer, MD, PhD, Elisabeth G.E. de Vries, MD, PhD and Jakob Korf, PhD

From the Departments of Biological Psychiatry (S.R., J.C.B., J.A.B., J.K.), Pathology and Laboratory Medicine (I.P.K.), Gastroenterology and Hepatology (E.B.H.), and Medical Oncology (P.H.B.W., E.G.E.V.), University Hospital Groningen, the Netherlands.

Address correspondence and reprint requests to Sascha Russo, MD, Department of Psychiatry, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. E-mail: s.r.russo{at}acggn.azg.nl

Objective: Treatment with recombinant interferon is associated with high rates of psychiatric comorbidity. We investigated the relation between catabolism of the essential amino acid tryptophan, being rate-limiting of peripheral and cerebral serotonin formation, and psychiatric symptoms in patients undergoing combination treatment with interferon-{alpha} and ribavirin.

Patients and Methods: Eighteen patients with viral hepatitis C who received interferon were included. A psychiatrist screened patients before and while on interferon-{alpha} treatment for 2 months, using a structured diagnostic interview. Fasting plasma tryptophan and platelet serotonin levels were measured at each visit.

Results: At baseline no evident psychopathology was observed. After 2 months of interferon treatment, 10 patients experienced increased irritability. No other structural psychopathology was observed. Decreased plasma tryptophan level correlated with the presence of irritability (p = .047). Platelet serotonin levels were found to be decreased during treatment (p = .002).

Conclusions: Aggressive impulse dysregulation is highly prevalent in patients receiving interferon treatment. This is associated with decreased plasma tryptophan levels which may lead to attenuated peripheral and central serotonergic neurotransmission.

Key Words: interferon • tryptophan • inflammation • serotonin • irritability

Abbreviations: 5-HT = serotonin; DSM = Diagnostic Statistical Manual.




This article has been cited by other articles:


Home page
 PsychosomaticsHome page
M. Bannink, W. H.J. Kruit, A. R. Van Gool, S. Sleijfer, B. van der Holt, A. M.M. Eggermont, G. Stoter, and M. W. Hengeveld
Interferon-{alpha} in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated
Psychosomatics, February 1, 2008; 49(1): 56 - 63.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Psychosomatic Society